Calcific uremic arteriolopathy treated with cinacalcet, paricalcitol, and autologous growth factors

Journal of Cutaneous Medicine and Surgery

Volumn 15, Issue 2, 2011, Pages 121-124

  Kakagia, Despoina ^a,b   Kriki, Pelagia ^a   Thodis, Elias ^a   Roumeliotis, Athanasios ^a   Vargemezis, Vassilios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b FEBOPRAS ^*  (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; GROWTH FACTOR; LANTHANUM CARBONATE; LOW MOLECULAR WEIGHT HEPARIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARICALCITOL;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOGLOBULIN A NEPHROPATHY; MEDICAL HISTORY; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; SKIN CALCIFICATION; SKIN ULCER; SYSTEMIC THERAPY; THROMBOSIS;

BONE DENSITY CONSERVATION AGENTS; CALCIPHYLAXIS; DEBRIDEMENT; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; NAPHTHALENES; PARATHYROID NEOPLASMS; WOUND HEALING;

EID: 79953864750     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2011.10052     Document Type: Article

References (10)

1. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998;32:384-91, doi:10.1053/ajkd.1998. v32.pm9740153. (Pubitemid 28411210)
2. Rogers NN, Teubner DJO, Coates TH. Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial 2007; 20:150-7, doi:10.1111/j.1525-139X.2007.00263.x.
3. Canella G, Messa P. Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both? J Nephrol 2006;19: 399-402. (Pubitemid 44823193)
4. Velasco N, MacGregor MS, Innes A, Mackay IG. Successful treatment of calciphylaxis with cinacalcet. An alternative to parathyroidectomy? Nephrol Dial Transplant 2006;21:1999-2004, doi:10.1093/ndt/gfl114. (Pubitemid 43985736)
5. Vargemezis V, Liakopoulos V, Kriki P, et al. Pivotal role of paricalcitol in the treatment of calcific uremic arteriolopathy in the presence of parathyroid adenoma. Am J Kidney Dis 2009;55:144-7, doi:10.1053/j.ajkd.2009.03. 015.
6. Andress D. Nonclassical aspects of differential vitamin D receptor activation. Drugs 2007;67:1999-2012, doi:10.2165/00003495-200767140-00003.
7. Alborgi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease. A randomized double-blind pilot trial. Hypertension 2008;52:249-55, doi:10.1161/HYPERTENSIONAHA.108.113159.
8. Redman R, Misita CP, Stafford DW, et al. Warfarin-associated calciphylaxis in a patient without renal failure or hyperparathyroidism. Investigation of matrix GLA protein. Blood 2005;106: 3969A.
9. Thodis E, Kriki P, Kakagia D, et al. Rigorous Vibrio vulnificus soft tissue infection of the lower leg in a renal transplant patient managed by vacuum therapy and autologous growth factors. J Cutan Med Surg 2009;13:209-14.
10. Atri SC, Misra J, Bisht D, Misra K. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery 1990;108:508-12. (Pubitemid 20309776)